Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data.

摘要: Purpose Tobramycin inhalation powder (TIP), the first dry-powder inhaled antibiotic for pulmonary Pseudomonas aeruginosa infection, is associated with reduced treatment burden, increased patient satisfaction, and higher self-reported adherence cystic fibrosis (CF) patients. We compared in CF patients newly treated TIP those traditional tobramycin solution (TIS), using US insurance claims data. Patients methods From Truven MarketScan® database, we identified chronically infected P. who had been prescribed between May 1, 2013 to December 31, 2014, or TIS September 2010 April 30, 2012 at least 12 months of continuous medical pharmacy benefits prior following prescription. levels were assessed. Results A total 145 eligible cohort 306 cohort. Significant differences age distribution (25.0 vs 21.9 years TIS, respectively, P=0.017), type health plan (P=0.014), employment status (72.4% 63.4% full-time employment, P=0.008), some comorbidities observed two cohorts. Although a univariate analysis found no significant (odds ratio [OR] 1.411, 95% confidence interval [CI] 0.949-2.098), was moderately multivariable analysis, once various demographic clinical characteristics adjusted for. These included geographic location (OR: 1.566, CI: 1.016-2.413) certain comorbidities. Conclusion This study data supports previous findings that better TIS; however, further studies will be required fully elucidate TIS.